Filing summary: Edge Therapeutics, Inc. — Form 10-Q for Q2 2017
Entity discrepancy: The filing is for Edge Therapeutics, Inc., not PDS Biotechnology Corp. The summary below reflects the filing text provided; verify that it is the intended filing.
Business context and reporting period
Quarter ended June 30, 2017; financial statements are unaudited. Edge was a clinical-stage biotechnology company developing drug-delivery candidates using its Precisa platform. Its lead candidate, EG-1962, was in a Phase 3 trial for aneurysmal subarachnoid hemorrhage (aSAH). The company reported no approved products and no commercial product revenue.
Financial performance and position
- Revenue: No product revenue; the company stated it did not expect product-sale revenue in the near term.
- Q2 2017: R&D expense was $9.0 million, up 50% year over year; G&A was $4.2 million, up 27%. Total operating expenses were $13.1 million, and net loss was $13.5 million, versus $9.4 million in Q2 2016. Loss per share was $0.44 versus $0.33.
- First half 2017: R&D expense was $16.6 million, up 46%; G&A was $8.4 million, up 20%. Total operating expenses were $24.9 million, and net loss was $25.7 million, versus $18.5 million in the first half of 2016. Loss per share was $0.86 versus $0.64.
- Cash flow: Operating cash use was $20.1 million for the first half, compared with $17.3 million a year earlier. Investing cash use was $0.1 million. Financing provided $22.5 million, including $17.4 million net from an April registered direct stock offering and $5.0 million from debt. Cash and cash equivalents increased by $2.3 million to $108.7 million.
- Liquidity and debt: Current assets were $109.4 million and current liabilities $11.6 million. Debt on the balance sheet totaled about $20.2 million, including $3.1 million current and $17.1 million long term; the loan’s stated principal was $20.0 million. The Hercules loan carried a 9.15% effective rate and was interest-only through March 2018, with scheduled principal repayment thereafter.
- Margins: Not meaningful because the company had no product revenue.
Material changes versus the prior comparable period
- Q2 net loss increased $4.1 million (44%); first-half net loss increased $7.1 million (38%). Higher clinical-trial and internal R&D costs were the main drivers; higher personnel, professional and other costs also contributed.
- Net interest expense rose in both comparison periods, reflecting debt interest, partly offset by increased interest income.
- Cash was broadly stable versus December 31, 2016, but that reflected equity and debt financing offsetting operating cash use.
- In April 2017, Edge sold 1.8 million shares for $18.0 million gross proceeds and approximately $17.4 million net proceeds. In May it drew the second $5.0 million tranche under its Hercules facility.
Outlook, risks, contingencies and unusual items
- Management expected existing cash to fund anticipated requirements through the full NEWTON 2 data readout, then expected in late 2018. The interim analysis was expected in early 2018; timing and continuation to full readout depended on results. Management cautioned that its cash runway estimate could prove wrong.
- NEWTON 2 was a randomized Phase 3 comparison of EG-1962 with oral nimodipine. The company also expected 2017 data from a small Phase 1 intracisternal EG-1962 study and planned to complete EG-1964 formulation work and begin nonclinical studies in 2017.
- Edge expected continued significant expenses and operating losses, and had no committed source of capital. It said future funding might require equity, debt, collaborations or licensing; failure to obtain financing could delay, scale back or discontinue development.
- On June 30, Edge entered into amended development and manufacturing/supply agreements with Oakwood for EG-1962. The development agreement provided for up to $4.5 million of milestone payments; a $1.5 million payment was made in July 2017. The supply agreement also provided for up to $2.25 million of development and regulatory milestones and potential royalties.
- Other material exposures include up to $14.75 million of Evonik development, regulatory and sales milestones, plus sales royalties. Hercules debt is secured by substantially all assets other than intellectual property and has restrictive covenants and default provisions.
- The company reported no material litigation, no material changes to previously disclosed risk factors, and no off-balance-sheet arrangements. It disclosed an ongoing IRS audit of its 2015 tax year but did not expect material adjustments. A full valuation allowance applied to deferred tax assets.
Important facts for investors to verify
- Confirm the filing identity: the supplied 10-Q names Edge Therapeutics, not PDS Biotechnology Corp.
- Review NEWTON 2 enrollment, interim-analysis timing and any subsequent trial or regulatory updates.
- Assess cash burn against the stated late-2018 runway, including the July 2017 Oakwood payment and future milestone obligations.
- Review debt terms, repayment schedule, covenants and potential financing needs.
- Verify clinical, manufacturing and regulatory risks for EG-1962 and development progress for EG-1964.